Dawson James analyst Jason H. Kolbert reiterated a Buy rating and $5.00 price target on Kintara Therapeutics, Inc (NASDAQ: KTRA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE